ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2391

Sustained Rheumatoid Arthritis Remission and Low Disease Activity: Analysis of 13 Years of Follow up in Clinical Practice

G. Avila1, Arnald Alonso1, María América López-Lasanta1, Andrea Pluma-Sanjurjo2, C. Diaz2 and Sara Marsal1, 1Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 2Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biologic agents, Disease Activity, remission and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Impact of Various Interventions and Therapeutic Approaches

Session Type: Abstract Submissions (ACR)

Background/Purpose

Biological therapies (BTs) have greatly improved the outcomes in RA patients and nowadays clinical remission (REM) and low disease activity (LDA) have become realistic goals. Only few studies have examined sustained REM and LDA in clinical practice during large periods of time. Our objective was to analyze the duration of clinical REM and LDA in RA patients in clinical practice in a university hospital

Methods

RA patients treated with ≥ 1 anti-TNF (infliximab, etanercept, adalimumab) during the period December’99-March’13 were included. Only those treatments with ≥ 12 weeks of follow-up were analyzed. A large number of data were collected (gender, erosions, nodules, RF, ACPA, disease duration, previous BTs and concomitant corticosteroids/DMARDs…etc). DAS28 score was recorded every 3 months in all patients

DAS28 records for each patient were interpolated to increase time resolution on the disease activity variations. We performed a parametric survival analysis in order to analyze the time until each patient reaches the first sustained period of low activity (LDA and REM). Survival curves were analyzed according to (i) DAS28 threshold that determines a low activity, (ii) minimum period of time in which one patient must be below DAS28 threshold to be considered as sustained low activity. DAS28 thresholds were 2.6 for REM and 3.2 for LDA. The periods to consider sustained low activity were 12, 24, 48 and 96 wks. The Cox regression model was used to evaluate differences in survival times. To analyze the differences between anti-TNFs, the model included DAS28 at baseline, gender and disease duration

Results

222 RA patients were included (87% female, 78% erosive, 75% RF (+), 77% ACPA (+)). 452 BTs met the inclusion criteria and were analyzed. In the global survival analysis we found that 44%, 20% and 10% of patients started a sustained REM period of at least 12, 24 and 96 wks during the first year of treatment. The analysis stratified by clinical variables showed that the absence of erosions was associated with sustained REM for periods longer than 48 weeks (P-value=7.94e-03; HR=0.49[0.32-0.76]). The differential analysis between anti-TNFs showed higher clinical remission rates in patients treated with Etanercept (ETN) compared to infliximab when longer periods were analyzed. Large periods of sustained LDA were also associated to ETN (P-value=8.1e-04; HR=2.42 [1.57-3.73]). Figure 1 shows heat maps representing (1) DAS28 for each treatment and time in low activity (external columns), (2) comparative analysis between treatments (central columns)

Conclusion

In our series of RA patients treated with anti-TNF therapies it was observed that 20% of patients initiate sustained clinical remission for at least 24 weeks during the first year of treatment. Patients treated with ETN are more likely to reach large periods of clinical remission and low disease activity measured by DAS28 score

 


Disclosure:

G. Avila,
None;

A. Alonso,
None;

M. A. López-Lasanta,
None;

A. Pluma-Sanjurjo,
None;

C. Diaz,
None;

S. Marsal,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sustained-rheumatoid-arthritis-remission-and-low-disease-activity-analysis-of-13-years-of-follow-up-in-clinical-practice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology